Implication of heme oxygenase-1 in the sensitivity of nasopharyngeal carcinomas to radiotherapy by Shi, Lei & Fang, Jun
BioMed  Central
Page 1 of 5
(page number not for citation purposes)
Journal of Experimental & Clinical 
Cancer Research
Open Access Research
Implication of heme oxygenase-1 in the sensitivity of 
nasopharyngeal carcinomas to radiotherapy
Lei Shi1 and Jun Fang*2
Address: 1Department of Otorhinolaryngology, the first affiliated hospital of China Medical University, Shenyang, 110001, P. R. China and 
2Laboratory of Microbiology & Oncology, Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto 860-0082, Japan
Email: Lei Shi - sxlsxl@hotmail.com; Jun Fang* - fangjun@ph.sojo-u.ac.jp
* Corresponding author    
Abstract
High expression of the inducible isoform of heme oxygenase (HO-1) is well known in various solid
tumors in human and experimental animal models. To investigate the relationship between HO-1
and nasopharyngeal carcinomas, especially its involvement in the response of nasopharyngeal
carcinomas to radiotherapy, thirty-two nasopharyngeal carcinomas were semi-quantitatively
analyzed by RT-PCR, and the expression of HO-1 was correlated with the consequence after novel
radiotherapy, which was evaluated by the reduction of tumor size. Among 32 nasopharyngeal
carcinomas, HO-1 expression was found in19 samples (59.4%), in which 9 patients (47.4%) showed
no response to radiotherapy. Interestingly, in 13 nasopharyngeal carcinoma patients with negative
expression of HO-1, radiotherapy exhibited to be effective (9 patients, 69.2%) or responsive (3
patients, 23.1%). In this study, we first demonstrated the expression of HO-1 in nasopharyngeal
carcinomas, and more important, these findings strongly suggest the potential of HO-1as a useful
index in identifying patients with well response to radiotherapy, further these data indicate a new
therapeutic for nasopharyngeal carcinoma by inhibiting HO-1 activity, which warrants further
investigation.
Background
Heme oxygenase (HO) catalyzes the rate-limiting step of
heme degradation, leading to formation of biliverdin, car-
bon monoxide (CO), and free iron [1,2], which play cru-
cial roles in the adaptation to and/or defense against
oxidative stress and cellular stress. HO-1 is a member of
the hear shock protein family (HSP-32), and its expres-
sion is triggered by diverse stress-inducing stimuli includ-
ing hypoxia [3], heavy metals [4], UV irradiation [5],
reactive oxygen species (ROS) and reactive nitrogen spe-
cies [5-7]. It is believed that induction of HO-1 protects
cells from these toxic stimuli by multiple mechanisms: (a)
decreasing the prooxidant level (heme) [8]; (b) increasing
the antioxidant level (bilirubin) [9]; (c) producing the
antiapoptotic molecule CO [10]; (d) inducing ferritin,
which removes and detoxifies free ferric ion [11]; (e) pre-
venting overstimulation of the immune response [12].
Indeed, inhibition of HO-1 by using specific HO inhibi-
tors such as zinc protoporphyrin or tin protoporphyrin
extended the pathological consequences of disorders
involving these stress-inducing stimuli: graft rejection
[13], ischemia-reperfusion injury [14], cisplatin nephro-
toxicity [15], and endotoxin-induced septic shock [12]. In
contrast, HO-1 inducers such as cobalt protoporphyrin
had beneficial effects on certain diseases [14,16].
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More important, it is now well known that expression of
high levels of HO-1 occurs in various tumors [17], and
that HO-1 has an important role in rapid tumor growth
because of its antioxidative and antiapoptotic effects [17].
HO-1 was thus considered to be a key molecule for
tumors against the attack from the host and chemother-
apy and radiotherapy by protecting tumor cells from oxi-
dative insults. It is interesting to note that several tumors,
including renal cell carcinoma [18] and prostate tumors
[19] in human, express a high level of HO-1. However,
very little is known concerning the relationship of HO-1
expression and clinical features in nasopharyngeal carci-
nomas (NPC). In this study, we have correlated HO-1
expression and the clinical status of nasopharyngeal carci-




Thirty-two patients diagnosed as NPC from the Depart-
ment of Otorhinolaryngology at the first affiliated hospi-
tal of China Medical University in 2004 and 2005, were
selected for this study. Of the 32 patients, the male/female
ratio was 20:12 and the mean age was 58.9 years (range
36–78) (Table 1). The tumor specimens were obtained by
pharyngoscopical biopsies. No treatments for the malig-
nant tumor were performed prior to this study. Staging of
the tumors was carried out according to the TNM classifi-
cation [20]. The TNM categories were determined by clin-
ical measurement and by a CT scan. The histological grade
was examined and classified according to the Interna-
tional Union Against Cancer (UICC) scheme (G1, well
differentiated; G2, poorly differentiated; G3, undifferenti-
ated). All patients involved were subjected to radiother-
apy (60Coγ radiation, 3 Gy each time, one radiation every
two days, totally 3 times), one year after which the effect
of radiotherapy was evaluated by means of tumor size
using clinical measurement and CT scan.
Reverse Transcriptase-Polymerase Chain Reaction (RT-
PCR) Assay for Expression of HO-1 mRNA in NPC 
specimens
Total RNA from NPC was extracted by using TRIzol rea-
gent (Life Technologies., Inc., Grand Island, NY), accord-
ing to the manufacturer's instruction. The RT-PCR assay to
detect HO-1 expression was performed according to the
method reported by Abraham [21]. The cDNA product
obtained by RT with random primers was amplified by
PCR. The nucleotide sequences of the oligonucleotide
primers used for PCR are as follows: HO-1 antisense 21-
mer, 5'GATGTTGAGCAGGAACGCGAT'; HO-1 sense 21-
mer, 5' CAGGCAGAGAATGCTGAGTTC' to obtain a 555
bp HO-1 cDNA (nucleotides 79–633 of the coding
sequence). After an initial denaturing step at 94°C, 25
PCR cycles were performed as follows: denaturing for 1
min at 94°C, primer annealing for 1 min at 56°C, and
DNA synthesis for 1 min at 72°C. The mRNA for glyceral-
dehyde-3-phosphate dehydrogenase (G3PDH) was exam-
ined as a standard mRNA expressed in the cells in the
same manner as for HO-1 except that 30 PCR cycles were
used. The nucleotide sequences of the primer for RT-PCR
for G3PDH are as follows: antisense 24-mer, 5'
CATGTGGGCCATGAGGTCCACCAC3'; sense 20-mer, 5'
TGAAGGTCGGAGTCAACGGATTTGGT3' to obtain a 983
bp G3PDH cDNA fragment. PCR products then under-
went electrophoresis on ethidium bromide-stained 1%
agarose gels.
Semi-quantitative analysis of HO-1 mRNA expression by 
RT-PCR
HO-1 mRNA expression by RT-PCR was semi-quantified
by a visual grading system in which the intensity of DNA
band from electrophoresis was categorized as negative (N,
no or very low expression, no apparent band), moderate
(M, apparent band with moderate thickness) and high (H,
clear and thick band) expression (Fig. 1).
Table 1: Correlation of HO-1 expression with clinicopathological features of nasopharyngeal carcinoma
Variable No. of patients (HO-1 expression) P value c
Total H + M a N b
Age ≤ 61 18 11 7 0.673
> 61 14 8 6
Sex Male 20 13 7 0.873
Female 12 6 6
Stage I + II 13 5 8 0.266
III + IV 9 14 5
Histological differentiation G1 17 7 10 0.174
G2 + G3 15 12 3
a Positive (H + M) expression of HO-1.
b Negative (N) expression of HO-1.
c Chi square test, P < 0.01 significant.Journal of Experimental & Clinical Cancer Research 2008, 27:13 http://www.jeccr.com/content/27/1/13
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Statistical analysis
The statistical significance of differences between HO-1
expression grade and various clinicopathologic features
(sex, stage, differentiation etc.) were assessed by the chi-
square test for independence. All of the data are expressed
as means ±SE. Student's t text was used to determine the
significance between each experimental group. The differ-
ence was considered statistically significant when P <
0.05.
Results
Expression of HO-1 in NPC
Among 32 NPCs, 19 samples expressed HO-1 at different
degree, as demonstrated by RT-PCR, in which 11 NPCs
showed moderate expression of HO-1 and 8 NPCs exhib-
ited high level of HO-1 expression; meanwhile, 13 NPCs
(40.6%) showed negative expression (Fig. 1).
Clinicopathological profiles of the patients related with 
HO-1 expression
To evaluate the relationship of HO-1 expression with the
clinicopathological profiles of NPC, HO-1 expression was
classified to two group, positive expression (H + M) and
negative expression (N); tumor stage and histological dif-
ferentiation of tumors were classified as I + II and III + IV,
G1 and G2 + G3 respectively. As showed in Table 1, no sig-
nificant difference of HO-1 expression was found between
each investigated group in all observed factors – age, sex,
tumor stage and histological differentiation of tumors.
HO-1 expression associated with the effect of 
radiotherapy in NPC patients
Radiotherapy is one of the most important treatments for
NPC, by generating cytotoxic reactive oxygen species
(ROS) such as singlet oxygen (1O2), hydroxyl radicals
(·OH) etc.. Because of the antioxidative and antiapop-
totic role of HO-1, we hypothesized that HO-1 expression
may render resistance of NPC patients against radiother-
apy, which is a crucial problem in clinic for NPC treat-
ment. To investigate this association, above mentioned 32
NPC patients were subjected to conventional radiother-
apy. One year after the treatment, the therapeutic effect
was evaluated by the reduction of tumor size as measured
by CT scan. As showed in Fig. 2, HO-1 negative patients
exhibited an average of 49.6% of tumor regression after
radiotherapy, whereas high expression of HO-1 induced a
great resistance to radiotherapy, with a significantly
decreased tumor regression rate of 6.9% (P < 0.0005 vs
HO-1 negative group); in between, treatment group with
moderate HO-1 expression showed an average tumor
regression of 29.1%. These data strongly supported our
hypothesis about the association of HO-1 expression with
the clinical effect of radiotherapy for NPC.
Discussion
Nasopharyngeal carcinoma (NPC) is relatively rare in
many countries in the world, for example, in U.S. it repre-
sents only 0.2% of all malignancies. However, in a
number of endemic areas it is the most common tumor
found, comprising 18% to 25% of all cancers. These
endemic areas include southern China, Hong Kong, Tai-
wan, Kenya, the Philippines, Singapore, Tunisia, Sudan
and Uganda. In contrast to this, the prevalence of NPC in
neighboring oriental countries, including Japan is quite
low. The incidence of NPC in northern China was very
low, however, recently it has been found to be increasing
gradually.
The mainstay of treatment of NPC is radiation. This is due
both to the inaccessibility of the tumor to surgery, and
also to the surprising radiosensitivity of the lesion. NPC is
also one of the most challenging tumors for the radiother-
Expression of HO-1 in nasopharyngeal carcinomas Figure 1
Expression of HO-1 in nasopharyngeal carcinomas. Nasopharyngeal carcinoma specimens were obtained by pharyngoscopical 
biopsies and were subjected to RT-PCR for determination of HO-1 mRNA expression. HO-1 mRNA expression by RT-PCR 
was semi-quantified by intensity of DNA band from electrophoresis as negative (N, No. 3, 5, 6, 12, 13, 15, 20, 21, 24, 25, 26, 
27, 30), moderate (M, No. 8, 9, 10, 11, 16, 17, 18, 19, 22, 31, 32) and high (H, No. 1, 2, 4, 7, 14, 23, 28, 29) expression.Journal of Experimental & Clinical Cancer Research 2008, 27:13 http://www.jeccr.com/content/27/1/13
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apist to treat, because of the close proximity of the tumor
to many vital structures. Besides, chemotherapy may be
used as an adjunct to radiation therapy, and surgery plays
a supportive role in the treatment of NPC. Even though
radiotherapy is a relatively effective treatment for NPC in
clinic, the 5-year survival rate of NPC patients after radio-
therapy is less than 50%, it is thus crucial to study on the
factors affecting the treatment, thus finding out a way to
increase the therapeutic efficacy for NPC is greatly antici-
pated.
Regarding to radiotherapy, its anticancer mechanisms are
mainly due to ionization of the water molecules to pro-
duce highly cytotoxic free radicals (1O2, ·OH radicals etc.)
by photons and the electrons present in the radiation
source. Radiation can also affect the processes of the cell
cycle necessary for cell growth, cell senescence, and apop-
tosis. Namely, induction of ROS and apoptosis attributes
to the therapeutic effect of radiotherapy. Interestingly,
recently it has been reported that HO-1 is a major antiox-
idative and antiapoptotic molecule [18] and plays a very
important role for rapid growth of solid tumor [22,23].
Administration of a specific HO inhibitor zinc protopor-
phyrin resulted in remarkable increase of intracellular
ROS, which subsequently induced the apoptosis to tumor
cells [23,24]. Because of the potent antioxidative and cyto-
protective role of HO-1, clinical application of the
enzyme has also been suggested in various disorders asso-
ciated with the generation of ROS, including atherosclero-
sis, hypertension, acute renal injury, toxic nephropathy,
transplant rejection, endotoxic shock, chronic obstructive
lung diseases, gastrointestinal diseases, Alzheimer's dis-
ease, and others [17]. Inhibition of HO-1 by HO inhibitor
zinc protoporphyrin or tin portoporphyrin has resulted in
the worsening of the disease, whereas administration of
HO-1 inducers such as cobalt protoporphyrin, hemin and
trinitrobenzene sulfonic acid or HO-1 gene transfer had
beneficial effects in certain other diseases [17]. More
important, HO-1 expression has been observed in various
human cancers [17-19], which suggested the potential
association of HO-1 with cancer.
Along this line, in this study, we investigated the expres-
sion of HO-1 in NPCs. Similar with other reports regard-
ing HO-1 and cancers [17-19,25], 59.4% NPCs from
patients involved in this study were found to express HO-
1, in which 25% showed high expression and 34.4% were
with low or moderate expression (Fig. 1). The expression
of HO-1 in NPCs seems not to relate with tumor stage and
histological differentiation (Table 1). According to the
above properties of HO-1, we thus hypothesized that HO-
1 may play an important role in NPC patients resistant to
radiotherapy. As expected, significant decrease of efficacy
of radiotherapy was found in NPC patients with high
expression of HO-1 (Fig. 2).
Conclusion
Taken together, these data strongly suggest that expression
of HO-1 in NPCs is associated with the sensitivity to radi-
otherapy, which high expression of HO-1 induces to
resistance to radiotherapy. Thus HO-1 may be very useful
for the prognosis of NPC patients receiving radiotherapy.
More important, it has been reported that chemothera-
peutic response of tumor cells by various conventional
ROS-generating anticancer drugs and authentic ROS, was
greatly enhanced by combination of a water-soluble HO
inhibitor polyethylene glycol-conjugated zinc protopor-
phyrin (PEG-ZnPP) [26,27]. We thus anticipated that, for
those NPC patients resistant to radiotherapy, combined
treatment by radiotherapy and HO inhibitors, such as
PEG-ZnPP, may exhibit superior therapeutic effect, which
needs further investigation.
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Association of HO-1 expression with the effect of radiother- apy in nasopharyngeal carcinoma patients Figure 2
Association of HO-1 expression with the effect of radiother-
apy in nasopharyngeal carcinoma patients. A) shows the 
results between HO-1 negative group (N) and positive group 
(H + M). The comparison data among each treatment group 
(H, M and N) is showed in B). Data are described as Mean ± 
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